Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 10
1999 9
2000 23
2001 31
2002 33
2003 25
2004 66
2005 83
2006 96
2007 127
2008 181
2009 268
2010 408
2011 480
2012 633
2013 711
2014 792
2015 839
2016 911
2017 923
2018 759
2019 654
2020 614
2021 129
Text availability
Article attribute
Article type
Publication date

Search Results

7,729 results
Results by year
Filters applied: . Clear all
Page 1
Everolimus.
Hasskarl J. Hasskarl J. Recent Results Cancer Res. 2018;211:101-123. doi: 10.1007/978-3-319-91442-8_8. Recent Results Cancer Res. 2018. PMID: 30069763 Review.
Everolimus shows promising clinical activity in additional indications. ...For a review on everolimus as immunosuppressant, please consult other sources....
Everolimus shows promising clinical activity in additional indications. ...For a review on everolimus as immunosuppressant, pl
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F; TRANSFORM Investigators. Pascual J, et al. J Am Soc Nephrol. 2018 Jul;29(7):1979-1991. doi: 10.1681/ASN.2018010009. Epub 2018 May 11. J Am Soc Nephrol. 2018. PMID: 29752413 Free PMC article. Clinical Trial.
Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kidney transplant require confirmation.Methods In a multicenter noninferiority trial, we randomized 2037 de novo kidney transplant recip …
Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment af …
Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.
Lee L, Ito T, Jensen RT. Lee L, et al. Expert Opin Pharmacother. 2018 Jun;19(8):909-928. doi: 10.1080/14656566.2018.1476492. Epub 2018 May 24. Expert Opin Pharmacother. 2018. PMID: 29757017 Free PMC article.
Since the initial approval of everolimus in 2011, there have been a number of important changes in therapeutic/diagnostic modalities as well as classification/staging systems of neuroendocrine tumors (NETs), which can significantly impact the use of everolimus in pa …
Since the initial approval of everolimus in 2011, there have been a number of important changes in therapeutic/diagnostic modalities …
Everolimus and sirolimus in transplantation-related but different.
Klawitter J, Nashan B, Christians U. Klawitter J, et al. Expert Opin Drug Saf. 2015 Jul;14(7):1055-70. doi: 10.1517/14740338.2015.1040388. Epub 2015 Apr 26. Expert Opin Drug Saf. 2015. PMID: 25912929 Free PMC article. Review.
INTRODUCTION: The inhibitors of the mammalian target of rapamycin (mTOR) sirolimus and everolimus are used not only as immunosuppressants after organ transplantation in combination with calcineurin inhibitors (CNIs) but also as proliferation signal inhibitors coated on dru …
INTRODUCTION: The inhibitors of the mammalian target of rapamycin (mTOR) sirolimus and everolimus are used not only as immunosuppress …
Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide.
Davies M, Saxena A, Kingswood JC. Davies M, et al. Orphanet J Rare Dis. 2017 Feb 15;12(1):35. doi: 10.1186/s13023-017-0581-9. Orphanet J Rare Dis. 2017. PMID: 28202028 Free PMC article. Review.
However, due to the historical predominance of everolimus in the oncology setting, some physicians who treat TSC patients may be unfamiliar with everolimus-associated adverse events (AEs) and appropriate management strategies. ...Since patients with TSC receive clin …
However, due to the historical predominance of everolimus in the oncology setting, some physicians who treat TSC patients may be unfa …
Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.
French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN. French JA, et al. Lancet. 2016 Oct 29;388(10056):2153-2163. doi: 10.1016/S0140-6736(16)31419-2. Epub 2016 Sep 6. Lancet. 2016. PMID: 27613521 Free article. Clinical Trial.
FINDINGS: Between July 3, 2013, and May 29, 2015, 366 patients were enrolled and randomly assigned to placebo (n=119), low-exposure everolimus, (n=117), or high-exposure everolimus (n=130). The response rate was 151% with placebo (95% CI 92-228; 18 patients) compare …
FINDINGS: Between July 3, 2013, and May 29, 2015, 366 patients were enrolled and randomly assigned to placebo (n=119), low-exposure evero
Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.
Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Belousova E, Frost MD, Sauter M, Brakemeier S, de Vries PJ, Berkowitz N, Voi M, Peyrard S, Budde K. Bissler JJ, et al. PLoS One. 2017 Aug 9;12(8):e0180939. doi: 10.1371/journal.pone.0180939. eCollection 2017. PLoS One. 2017. PMID: 28792952 Free PMC article. Clinical Trial.
OBJECTIVES: We examined the long-term effects of everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. METHODS: Following favorable results from the double-blind core phase of EXIST-2 (NCT00790400) …
OBJECTIVES: We examined the long-term effects of everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis …
Everolimus: Longer-Term CERTITUDE.
Mousa OY, Keaveny AP. Mousa OY, et al. Liver Transpl. 2019 Dec;25(12):1745-1746. doi: 10.1002/lt.25659. Liver Transpl. 2019. PMID: 31606937 Free article. No abstract available.
Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
Jerusalem G, de Boer RH, Hurvitz S, Yardley DA, Kovalenko E, Ejlertsen B, Blau S, Özgüroglu M, Landherr L, Ewertz M, Taran T, Fan J, Noel-Baron F, Louveau AL, Burris H. Jerusalem G, et al. JAMA Oncol. 2018 Oct 1;4(10):1367-1374. doi: 10.1001/jamaoncol.2018.2262. JAMA Oncol. 2018. PMID: 29862411 Free PMC article. Clinical Trial.
Estimated HR of PFS was 0.74 (90% CI, 0.57-0.97) for the primary objective of everolimus plus exemestane vs everolimus alone and 1.26 (90% CI, 0.96-1.66) for everolimus plus exemestane vs capecitabine alone. ...Serious adverse events were more frequent with …
Estimated HR of PFS was 0.74 (90% CI, 0.57-0.97) for the primary objective of everolimus plus exemestane vs everolimus alone a …
Therapeutic Drug Monitoring of Everolimus in Oncology: Evidences and Perspectives.
Falkowski S, Woillard JB. Falkowski S, et al. Ther Drug Monit. 2019 Oct;41(5):568-574. doi: 10.1097/FTD.0000000000000628. Ther Drug Monit. 2019. PMID: 30913132 Review.
The last consensus conference about the TDM of everolimus states that for the use of everolimus in oncology, "further studies are required to determine the clinical utility of TDM for everolimus in oncology settings." In this review, the authors will discuss …
The last consensus conference about the TDM of everolimus states that for the use of everolimus in oncology, "further studies …
7,729 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page